Valero Energy Corporation (VLO) Stock Price Today
Aura AI Summary
Key Stats
- $111.60BMarket Cap
- 2,526,888Volume
- EnergySector
- $413.2852W High
- $156.3952W Low
- 56 DaysTypical Hold Time
- $115.08BEnterprise Value
- 1.24%Div Yield
- 79% Sell | 21% BuyTrading Activity
Track Valero Energy Corporation (VLO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Valero Energy Corporation has traded between a low of $156.39 and a high of $413.28, highlighting its annual price range. Buy and sell Valero Energy Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Most Recent News
Nexalin, Armada, Roze AI, Mattel, and Accenture lead market gains on key deals and earnings beats
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...

Boeing shares rise as new union contract secures 737 production and avoids strike risk.
Boeing's stock rose following the approval of a new four-year union contract covering 13,000 engineers and 4,000 technical workers. The agreement prevents a potential strike that could have disrupted 737 production and delayed aircraft deliveries, pr...

Foghorn Therapeutics cuts price target after ending Lilly partnership and cutting 40% workforce
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.